Credit: Reuters/Michael Buholzer
A logo of Swiss pharmaceutical company Roche is pictured at a company's building in Rotkreuz, April 12, 2012.
'Roche is working with investigators to support the management of patients and their transition from aleglitazar treatment to other blood sugar control therapies,' Roche's chief medical offer and head of product development Hal Barron said in a statement on Wednesday.
The undisclosed safety questions were uncovered by a safety review conducted by an independent group of drug experts during a late-stage trial.
(Reporting By Katharina Bart)
